Trial Profile
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2023
Price :
$35
*
At a glance
- Drugs Tapinarof (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 26 May 2020 Results presented in the Dermavant Sciences Media Release.
- 12 May 2020 Results assessing secondary Efficacy and patient-reported Outcomes, published in the Journal of the American Academy of Dermatology
- 21 Feb 2019 According to a Dermavant Sciences media release, data from this study will be presented in a poster format and an oral presentation at the 2019 American Academy of Dermatology (AAD) Annual Meeting (March 1-5, 2019).